A pioneering study by researchers at the University of Tehran has revealed the therapeutic potential of the cytokine Interleukin-17 (IL-17a) in treating colorectal cancer (CRC). The findings mark a major advancement in immunotherapy approaches and open new avenues for targeted treatment strategies. This is reported by
IRNA, a partner of TV BRICS.

Based on a six-year analysis of 2,900 CRC patients, the research demonstrated that controlled elevation of IL-17a levels in blood and within the tumour microenvironment induces apoptosis (programmed cell death) and inhibits metastasis-related molecules. These mechanisms significantly improve the immune system’s ability to target and eliminate cancer cells.

The research confirmed that IL-17 enhances the expression of apoptotic and autophagy-related genes and proteins, accelerating the destruction of malignant cells. It also exerts a regulatory effect on B3GATN2, a molecule involved in mucin production, thereby potentially limiting the spread of CRC cells within the body.

Cutting-edge techniques including luminometry, flow cytometry, and electron microscopy were used to investigate cellular and ultrastructural changes. These analyses provided robust evidence of the cytokine’s efficacy in disrupting tumour cell integrity and progression, the source claimed.

The research team’s next phase will focus on designing smart nanocarriers to deliver IL-17 directly to cancerous tissues, enhancing precision and minimising side effects.

Photo:
iStock